Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-8266 · 2 trials · 1 indication
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory hematology value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory hematology value.
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory chemistry value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory chemistry value.
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory urinalysis value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory urinalysis value.
Participants rested for at least 10 minutes prior to having vital sign measurements obtained.
Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Heart rate measurements were obtained in the semirecumbent position and 3 sets of measurements were obtained approximately 1 minute apart.
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An abnormal ECG value was any AE reported under the System Organ Classes of Investigations or Cardiac that was related to an abnormal ECG value.
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.
Central ascending aortic blood pressure augmentation index (AIx) is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. AIx can be measured non-invasively by radial tonometry using aplanation tonometry of radial artery with the SphygmoCor Pulse Wave Analysis System Guide (SphygmoCor system). AIx was performed at prestudy to ensure an adequate waveform can be obtained. At each time point, a minimum of 2 AIx were completed in an attempt to obtain 2 acceptable quality assessments. A time weighted average was calculated. AIx was adjusted for heart rate. A decrease in the AIx of ≥5 percentage is considered clinically meaningful. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period. The 12-hour measurement was not collected (per protocol) in all periods of Panels A and B.
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-inf\] is a measure of the mean concentration levels of drug in the plasma after the dose. AUC\[0-inf\] was not collected, analyzed or summarized for participants receiving placebo.
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. For Panel A 1.0/0.8 mg MK-8266, the second dose was not well characterized due to limited sampling. Observed exposure likely underestimates the true exposure. Cmax was not collected, analyzed or summarized for participants receiving placebo.
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Tmax was not collected, analyzed or summarized for participants receiving placebo.
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Harmonic means +/- Pseudo standard deviations are displayed. t1/2 was not collected, analyzed or summarized for participants receiving placebo.
| Arm | Type | Description |
|---|---|---|
| Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN) | EXPERIMENTAL | MK-8266 single dose 0.3 mg |
| Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN) | EXPERIMENTAL | MK-8266 single dose 0.6 mg |
| Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN) | EXPERIMENTAL | MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours |
| Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN) | PLACEBO_COMPARATOR | Placebo to MK-8266 single dose |
| Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN) | EXPERIMENTAL | MK-8266 single dose 0.3 mg |
| Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN) | EXPERIMENTAL | MK-8266 single dose 0.6 mg |
| Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN) | EXPERIMENTAL | MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours |
| Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN) | PLACEBO_COMPARATOR | Placebo to MK-8266 single dose |
| Panel A, Healthy Male Participants, Sequence 1 | EXPERIMENTAL | MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose. |
| Panel A, Healthy Male Participants, Sequence 2 | EXPERIMENTAL | MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose. |
| Panel A, Healthy Male Participants, Sequence 3 | EXPERIMENTAL | MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo. |
| Panel A, Healthy Male Participants, Sequence 4 | EXPERIMENTAL | MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose. |
| Panel B, Healthy Male Participants, Sequence 1 | EXPERIMENTAL | MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na. |
| Panel B, Healthy Male Participants, Sequence 2 | EXPERIMENTAL | MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na. |
| Panel B, Healthy Male Participants, Sequence 3 | EXPERIMENTAL | MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na. |
| Panel B, Healthy Male Participants, Sequence 4 | EXPERIMENTAL | MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na. |
| Panel C, Mild/Moderate Hypertension, Sequence 1 | EXPERIMENTAL | Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na |
| Panel C, Mild/Moderate Hypertension, Sequence 2 | EXPERIMENTAL | Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na |
| Panel C, Mild/Moderate Hypertension, Sequence 3 | EXPERIMENTAL | Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na |
| Panel C, Mild/Moderate Hypertension, Sequence 4 | EXPERIMENTAL | Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na |
| Panel C, Mild/Moderate Hypertension, Sequence 5 | EXPERIMENTAL | Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na |
| Panel C, Mild/Moderate Hypertension, Sequence 6 | PLACEBO_COMPARATOR | Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na |
| Name | Type | Description |
|---|---|---|
| MK-8266 | DRUG | Oral capsules, 0.1 mg potency |
| Placebo | DRUG | Oral placebo capsules to match MK-8266 capsules |
| MK-8266 0.1 mg | DRUG | Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food. |
| MK-8266 1.0 mg | DRUG | MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. |
Inclusion criteria: * Participants are male or non-childbearing female. * Participant with essential hypertension (HTN), Grade 1 or 2 (as per European Society of Hypertension \[ESH\]) or isolated mild to moderate systolic HTN. High normal systolic BP ≥130 mmHg will be also allowed. Blood pressures ...
MK-8266 is an investigational small molecule being developed for the treatment of hypertension, a cardiovascular condition characterized by high blood pressure. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MK-8266 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is in early-stage clinical development for hypertension.
MK-8266 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Two Phase 1 trials have been completed, and the drug remains in early-stage testing.
MK-8266 has been studied in two completed Phase 1 clinical trials. NCT01025791 was a single-dose study in healthy male volunteers with hypertension, enrolling 25 participants. NCT01263314 evaluated safety, tolerability, and pharmacokinetics in elderly participants with high blood pressure, enrolling 16 participants.
No alternative names for MK-8266 have been disclosed. The drug is identified solely by its development code MK-8266 in clinical trial registrations and is not known to be marketed under any other name.